Management of alcohol dependence in patients with liver disease.

Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84

Comment on: "Management of alcohol dependence in patients with liver disease". CNS Drugs (2013) 1.07

Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statement. World J Gastroenterol (2014) 0.90

Pharmacotherapy for alcoholic patients with alcoholic liver disease. Am J Health Syst Pharm (2014) 0.86

Identification and management of alcohol withdrawal syndrome. Drugs (2015) 0.81

Alcohol addiction: toward a patient-oriented pharmacological treatment. Expert Opin Pharmacother (2013) 0.80

Alcoholic liver disease and hepatitis C virus infection. World J Gastroenterol (2016) 0.79

Pharmacotherapy of acute alcoholic hepatitis in clinical practice. World J Gastroenterol (2014) 0.78

Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review. Alcohol Clin Exp Res (2016) 0.77

Diagnostic challenges in alcohol use disorder and alcoholic liver disease. World J Gastroenterol (2014) 0.77

Management of Alcohol Use Disorder in Patients Requiring Liver Transplant. Am J Psychiatry (2015) 0.76

Scoparone affects lipid metabolism in primary hepatocytes using lipidomics. Sci Rep (2016) 0.76

Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med (2016) 0.75

The Genoa Method in Alcohol Dependence Treatment. Gastroenterology Res (2016) 0.75

Chronic Ethanol-Induced Impairment of Wnt/β-Catenin Signaling is Attenuated by PPAR-δ Agonist. Alcohol Clin Exp Res (2015) 0.75

Authors' reply to Rolland et al.: "Management of alcohol dependence in patients with liver disease". CNS Drugs (2013) 0.75

Risk factors and outcomes associated with alcohol relapse after liver transplantation. World J Hepatol (2017) 0.75

Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction (1993) 41.55

Actual causes of death in the United States. JAMA (1993) 28.34

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA (2006) 13.15

Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol (1997) 11.33

Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry (1997) 8.01

Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA (2007) 6.81

Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry (1992) 5.48

Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther (1979) 5.02

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry (2008) 4.91

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (2003) 4.79

Naltrexone in the treatment of alcohol dependence. N Engl J Med (2001) 4.68

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 3.66

Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet (2007) 3.62

Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry (1992) 3.55

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction (2004) 3.27

Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut (1997) 3.25

Acamprosate for alcohol dependence. Cochrane Database Syst Rev (2010) 3.03

Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res (2010) 2.70

Affiliation with Alcoholics Anonymous after treatment: a study of its therapeutic effects and mechanisms of action. J Consult Clin Psychol (1997) 2.63

EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol (2012) 2.52

Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA (2000) 2.47

Alcohol, oxidative stress and free radical damage. Proc Nutr Soc (2006) 2.29

Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev (2010) 2.21

Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA (1986) 2.20

Liver transplantation for patients with alcoholic liver disease: an open question. Dig Liver Dis (2011) 2.14

The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci (1979) 2.12

Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol (2002) 2.01

Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol (2011) 1.98

One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction (2000) 1.93

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol (2001) 1.80

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res (2004) 1.72

A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl (2011) 1.69

The risks associated with alcohol use and alcoholism. Alcohol Res Health (2011) 1.69

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry (2011) 1.69

Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs (2005) 1.59

Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol (2005) 1.56

Drug therapy for alcohol dependence. N Engl J Med (1999) 1.54

Alcohol consumption in the European community: uniformity and diversity in drinking patterns. Addiction (1993) 1.50

Accumbens neurochemical adaptations produced by binge-like alcohol consumption. Psychopharmacology (Berl) (2007) 1.50

Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis (2007) 1.49

Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol (1998) 1.49

Antispasticity drugs: mechanisms of action. Ann Neurol (1985) 1.48

A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol (1999) 1.46

Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol Clin Exp Res (1981) 1.45

Disulfiram treatment of alcoholism. Br J Psychiatry (1992) 1.45

FACTORS IN THE TREATMENT OF LAENNEC'S CIRRHOSIS. I. CLINICAL AND HISTOLOGICAL CHANGES OBSERVED DURING A CONTROL PERIOD OF BED-REST, ALCOHOL WITH-DRAWAL, AND A MINIMAL BASIC DIET. J Clin Invest (1949) 1.44

Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs (2005) 1.43

Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol (2007) 1.40

Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant (2009) 1.39

Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. Alcohol Clin Exp Res (2000) 1.38

Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med (2008) 1.34

Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res (2006) 1.32

Craving for alcohol: findings from the clinic and the laboratory. Alcohol Alcohol (1999) 1.31

The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev (2004) 1.30

Acute alcohol intoxication. Eur J Intern Med (2008) 1.29

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res (2004) 1.28

Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int (2003) 1.25

The actions of metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol (1981) 1.25

Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res (2004) 1.21

Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol (1995) 1.21

Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry (1996) 1.18

Alcoholic liver disease. World J Hepatol (2012) 1.16

Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav (2011) 1.15

Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl) (2003) 1.14

Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des (2011) 1.13

Alcoholic liver disease. Postgrad Med J (2000) 1.13

Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets (2010) 1.11

Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. Liver Transpl (2004) 1.10

How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology (2005) 1.08

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry (1997) 1.08

Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol (2000) 1.07

Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev (2009) 1.04

Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des (2010) 1.04

Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des (2010) 1.03

First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation. Liver Transpl (2003) 1.03

Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend (2003) 1.02

Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J (2003) 1.02

Reduced substance-abuse-related health care costs among voluntary participants in Alcoholics Anonymous. Psychiatr Serv (1996) 1.02

An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol (1996) 1.02

The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol (2002) 1.01

A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res (2008) 1.01

Individualised treatment in alcohol-dependent patients. Eur Arch Psychiatry Clin Neurosci (2010) 1.00

Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol (2005) 0.99

The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol (1999) 0.98

Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse (2006) 0.97

Housekeeping gene variability in the liver of alcoholic patients. Alcohol Clin Exp Res (2011) 0.97

Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl) (2002) 0.96

Comparing the diagnostic accuracy of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean cell volume in a general practice population. Alcohol Clin Exp Res (1999) 0.95

Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res (1994) 0.95

Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des (2010) 0.94

Mechanism of the antialcohol effect of gamma-hydroxybutyric acid. Alcohol (2000) 0.94

Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. CNS Drugs (2012) 0.94

[Stabilisation of abstinence by means of psychoeducation for patients with alcoholic liver disease awaiting liver transplantation]. Z Psychosom Med Psychother (2006) 0.93

The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs (2009) 0.92

Baclofen: a new drug for the treatment of alcohol dependence. Int J Clin Pract (2006) 0.92

Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res (2011) 0.92

Public and professional attitudes to transplanting alcoholic patients. Liver Transpl (2007) 0.92

Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther (1985) 0.92

Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Hum Psychopharmacol (2011) 0.91

Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol (1996) 0.91

Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57

Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet (2007) 3.62

Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64

Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med (2006) 2.55

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50

Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14

Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol (2011) 1.98

Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69

Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62

Increased serum high-density lipoprotein-cholesterol concentration in celiac disease after gluten-free diet treatment correlates with body fat stores. J Clin Gastroenterol (2009) 1.54

Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52

Primary renal angiosarcoma: a rare malignancy. A case report and review of the literature. Urol Oncol (2006) 1.47

Acute alcohol intoxication. Eur J Intern Med (2008) 1.29

The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25

Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet (2001) 1.15

Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des (2011) 1.13

Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol (2011) 1.11

Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11

Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav (2005) 1.09

Relationship between ghrelin levels, alcohol craving, and nutritional status in current alcoholic patients. Alcohol Clin Exp Res (2006) 1.09

How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology (2005) 1.08

Polymyalgia rheumatica in 2011. Best Pract Res Clin Rheumatol (2012) 1.05

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. Pharmgenomics Pers Med (2012) 1.04

Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des (2010) 1.04

Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev (2009) 1.04

Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica (2008) 1.01

The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response. Cytokine Growth Factor Rev (2013) 1.01

A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res (2008) 1.01

Primary angiosarcoma of the kidney: size is the main prognostic factor. Int J Urol (2007) 1.01

Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol (2009) 0.98

Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology (2011) 0.97

Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med (2014) 0.97

Use of novel technology-based techniques to improve alcohol-related outcomes in clinical trials. Alcohol Alcohol (2013) 0.97

Rapid regression of psoriasis in a coeliac patient after gluten-free diet. A case report and review of the literature. Digestion (2003) 0.97

HIV testing in hazardous drinking: a survey analysis. Subst Use Misuse (2010) 0.95

Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin Neuropharmacol (2003) 0.94

Cellular mediators of inflammation: tregs and TH17 cells in gastrointestinal diseases. Mediators Inflamm (2010) 0.94

The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. Front Psychiatry (2010) 0.93

Relationship between the hypothalamic-pituitary-thyroid axis and alcohol craving in alcohol-dependent patients: a longitudinal study. Alcohol Clin Exp Res (2008) 0.93

Affective and psychiatric disorders in celiac disease. Dig Dis (2008) 0.93

Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients. Alcohol Clin Exp Res (2008) 0.93

The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs (2009) 0.92

Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol (Oxf) (2012) 0.92

'Doctor, treat your patient, not your monitor!' Tremor-induced ECG artefacts mimicking torsades de pointes. BMJ Case Rep (2014) 0.91

Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Hum Psychopharmacol (2011) 0.91

Role of trait anxiety in persistent radicular pain after surgery for lumbar disc herniation: a 1-year longitudinal study. Neurosurgery (2010) 0.91

The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humans. Neuropsychol Rev (2012) 0.90

State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. J Neurosurg (2008) 0.90

IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol (2013) 0.89

Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms. Intern Emerg Med (2011) 0.89

Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. Alcohol (2008) 0.88

Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence. Curr Pharm Des (2010) 0.88

Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative? Int J Vasc Med (2011) 0.87

Pharmacological approaches to reducing craving in patients with alcohol use disorders. CNS Drugs (2014) 0.86

A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol (2010) 0.85

Alcohol use disorders in the elderly: a brief overview from epidemiology to treatment options. Exp Gerontol (2012) 0.85

Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet. Clin Transl Gastroenterol (2012) 0.85

Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy. Arterioscler Thromb Vasc Biol (2013) 0.85

Coenzyme Q 10 and cardiovascular risk factors in idiopathic sudden sensorineural hearing loss patients. Otol Neurotol (2007) 0.85

Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. Haematologica (2007) 0.84

Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis (2012) 0.83

Distinct expression of cyclooxygenase-1 and -2 in the human thymus. Eur J Immunol (2002) 0.83

Autoimmune hemolytic anemia with gel-based immunohematology tests. Am J Clin Pathol (2013) 0.83

Social phobia in coeliac disease. Scand J Gastroenterol (2008) 0.82

Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacol Biochem Behav (2008) 0.82

Coeliac disease and hearing loss: preliminary data on a new possible association. Scand J Gastroenterol (2007) 0.82

Effects of short-term moderate alcohol administration on oxidative stress and nutritional status in healthy males. Appetite (2007) 0.81

Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol (2010) 0.81

NSAID enteropathy: could probiotics prevent it? J Gastroenterol (2012) 0.81

Baclofen for outpatient treatment of alcohol withdrawal syndrome. J Fam Pract (2005) 0.81

A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. Mol Biol Rep (2012) 0.81

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest (2015) 0.81

Hormones and drinking behaviour: new findings on ghrelin, insulin, leptin and volume-regulating hormones. An ESBRA Symposium report. Drug Alcohol Rev (2009) 0.81

Identification and management of alcohol withdrawal syndrome. Drugs (2015) 0.81

Fecal calprotectin concentrations in alcoholic patients: a longitudinal study. Eur J Gastroenterol Hepatol (2011) 0.80